Replies to post #238586 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Brilacidin couldn't fill that spot since it isn't approved yet."

I guess that's true, but neither is GC4419, RRX-001 or amifostine. So they chose a non-radioprotective drug as a comparitor for 3 radioprotective candidates just because it was an approved treatment for the indication.

Hey...it's their study!
I guess if the indication was the focus Brilacidin may have received a mention since none of the radioprotective candidates has gone beyond Phase 2 either.

[PlentyParanoid]

KarinCA and Loanranger, good that you settled your 'differences'. My first post was based on a very hasty read of the review article, so your little tussle made me nervous. Now I have read the review again and intend to wade back into dangerous waters.

I am getting a feeling that the review is more an attention getter for RRx-001 than a serious review - short treatment of each drug with references to some significant articles and letters not to be found. For instance: the report of GC4419 phase 1 trial in OM, criticism for both palifermin HNC trials. The article does touch the criticism of palifermin trials, but without references for their mildly strange conclusions.

It will be interesting to see how well RRx-001 protection of bone marrow will extend into protection of oral mucosa. Based on the information the authors of the review provide and with my extremely limited knowledge of biology involved, RRx-001 modified red blood cells probably will accumulate in the environment of some (dense) tumors. Bumpkin explanation: they can't get in due to collapsed tumor blood vessels so they bleed into tumor environment. But to what extent? Accumulation will probably be in much lesser numbers than in bone marrow. My opinion, not a fact, which usually makes the opposite more likely fact.

I do agree with the authors of the review that future treatment of SOM will be a combination of drugs where one will work, using Sonis model, in early initiation/oxidation stage of cell damage, the other will act on cytokines and/or other inflammatory agents and may even promote healing process. It is helluva hard to design a single, tolerable compound that would be active in all 5 stages.